Top in rheumatology: New lupus drug, telehealth preferences
Click Here to Manage Email Alerts
The FDA recently approved the first new drug for systemic lupus erythematosus since 2011. It was the top story in rheumatology last week.
A review of new survey data on telehealth preferences was another top story. Most patients who responded to the survey said they will “always prefer” in-person appointments over telehealth appointments. Among those who had an in-person or telehealth rheumatology appointment since the beginning of the pandemic, 55% preferred future visits to be in-person, while 41% preferred telehealth.
Read these and more top stories in rheumatology below:
FDA approves Saphnelo, first new lupus treatment since 2011
The FDA has approved AstraZeneca’s anifrolumab-fnia, a first-in-class type I interferon receptor antagonist, for treatment of adults with moderate to severe systemic lupus erythematosus, according to a press release. Read more.
Poll: 80% of US patients will 'always prefer' in-person visits to telehealth after COVID-19
A new survey conducted by The Harris Poll for San Diego-based pharmaceutical company Neurocrine Biosciences found that 80% of U.S. patients will “always prefer” in-person physician visits to telemedicine. Read more.
Health care providers urged to create 'culturally safe medical home' for patients
Understanding the parameters of bias, race and racism is critical to creating an environment in which patients of all backgrounds feel comfortable, according to the keynote speaker at the 2021 Rheumatology Nurses Society annual conference. Read more.
A decade under Benlysta: Review touts how historic lupus drug continues to impact therapy
In the 10 years since its first FDA approval for systemic lupus erythematosus in 2011, belimumab has altered the “SLE treatment paradigm,” amassing a body of evidence establishing it as a disease-modifying therapy, according to a review article. Read more.
Collaboration between rheumatologists, primary care reduces delay in axial SpA diagnosis
Partnerships between rheumatologists and specially trained advanced practice providers in primary care can reduce diagnostic delay and shorten wait times in axial spondyloarthritis, according to data published in Arthritis Care & Research. Read more.